Press Releases :: VolitionRx Ltd (VNRX)

Nov 17, 2015 9:00 am EST

VolitionRx Granted Its Second U.S. Patent

Nov 12, 2015 7:00 am EST

VolitionRx to Present at Two Conferences in November

Nov 4, 2015 6:30 am EST

VolitionRx Announces Third Quarter 2015 Financial Results and Business Update

Oct 30, 2015 7:00 am EDT

VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET

Oct 22, 2015 7:00 am EDT

VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study

Oct 12, 2015 7:00 am EDT

VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics

Sep 22, 2015 7:00 am EDT

VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer

Sep 10, 2015 7:00 am EDT

VolitionRx Granted Its First U.S. Patent

Sep 9, 2015 8:00 am EDT

VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial

Sep 2, 2015 8:00 am EDT

VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015

rss_feed News RSS